BSECompany Update1 Nov 2026 · 1 Nov 2026, 07:08 pm

Investor Presentation

Shree Ganesh Remedies Ltd · 540737

✦ AI SummaryResults

Shree Ganesh Remedies Ltd has released an investor presentation for Q2 and H1FY27, highlighting a challenging start to the year due to subdued input costs and demand, but showing improvement in Q2 with a focus on core CRAMS business and new product development.

Analysis Scores

Earnings Impact4/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Shree Ganesh Remedies Ltd - 540737 - Announcement under Regulation 30 (LODR)-Investor Presentation

Attachments (1)

📄

37a0fb05-2914-414b-b796-9ae9322aace9.pdf

pdf

Download →
View document text
November 01, 2026 The BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 540737 Dear Sir/Ma’am, Sub: Investor Presentation With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Kindly take the same on your record. Thanking You, Yours faithfully For Shree Ganesh Remedies Limited Akanksha Company Secretary and Compliance Officer Enc. a/a Investor Presentation Q2 & H1FY27 Innovate. React. Transform. Inside the 19 Dahej Land Acquisition Setting the Stage for Large Scale Projects Forward 20 Driving Innovation Through Strategic R&D Investments Presentation Looking 21 State-of-the-Art R&D Infrastructure Statement 22 State-of-the-Art Pilot Infrastructure In so far as forecasts or 23 Accreditations that Speak to Our Comprehensive Standards expectations are 24 Driving Innovation and Growth expressed in this Quarterly Highlights presentation or where 25 Ensuring Health and Safety our statements concern 04 Management Commentary 26 Protecting the Environment With Sustainable Practices the future, these 05 P&L Summary forecasts, expectations or statements may 06 Balance Sheet Summary involve known or 07 Cash Flow Summary unknown risks and uncertainties. Actual results or developments Financial Highlights may vary, depending on changes in the 28 5 Year Summary operating environment. About the Business Shree Ganesh Remedies 29 Key Ratios 09 Excellence in Complex Chemistry Limited does not 30 P&L Summary assume an obligation to 10 Unparalleled Expertise in Advanced Chemical Synthesis update the forecasts, 31 Balance Sheet Summary 12 Unmatched Technology Prowess In Complex Chemical Reactions expectations or 32 Cash Flow Summary statements contained in 13 Tailored Solutions Through Mastered Chemistry and Technology this presentation. 14 Strategic Product Selection Criteria 15 Our Evolving Business Model 16 Collaborating With Industry Leaders Investment Merits 17 Ankleshwar Site Expansion Fuelling Our Growth Strategy 34 Investment Case 18 Infrastructure at Ankleshwar Site Shree Ganesh Remedies Limited Quarterly Highlights Management Commentary 04 P&L Summary 05 Balance Sheet Summary 06 Cash Flow Summary 07 QUARTERLY HIGHLIGHTS Management Commentary FY27 began on a challenging note for the Company. Subdued expect input costs to ease as geopolitical conditions stabilise, demand from Europe and a difficult operating environment and margins to normalise as our sales return to earlier levels. weighed on our first-quarter performance. Over the past Throughout, we remain focused on healthy profitability, three months, we have worked steadily through these including on the new products we are developing. challenges, and this is reflected in an improved performance in Q2FY27. As we work towards this recovery, we continue to build the businesses that will drive our next phase of growth. Our Much of this improvement has come from our core CRAMS business has made strong progress during the pharmaceutical intermediates business, where we sharpened quarter. On our specialty chemicals project for South-East our focus on the domestic market to make up for softer Asian markets, we have successfully completed the pilot trials, exports. Alongside this, we have begun to see improved and the batches are now undergoing stability testing, with traction from our European customers, which gives us commercial supplies expected from Q1FY28. A second confidence that the core business will recover to its earlier specialty chemicals product for the same region has cleared levels over the next few quarters. We have also broadened laboratory trials and moved to the pilot stage. In Europe, we our portfolio during the quarter by commencing commercial are making positive progress on two molecules for production of two new pharmaceutical intermediates, one for pharmaceutical and agrochemical applications. To support anti-diabetic and one for cardiovascular applications. Both this pipeline, construction of Block 7A is now complete and have received an encouraging response in the domestic trials have begun. market, and we plan to take them to export markets in the coming quarters. This year has brought its own set of challenges, and we have responded by strengthening our domestic presence, adding While volumes are on the path to recovery, they remain to our product portfolio and advancing our CRAMS pipeline. below earlier levels, and this has put some pressure on our With the core business recovering, new products gaining margins. Raw material prices added to this pressure, rising traction and new capacity coming online, we look forward to significantly and staying volatile through the quarter. We a stronger performance in the periods ahead. Gunjan Kothia Promoter, Head of Business Development & Innovation Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS P&L Summary -23% -59% -67% YoY Change Revenue EBITDA PAT YoY QoQ YoY PARTICULARS Q2FY26 Q1FY27 Q2FY27 H1FY26 H1FY27 (₹ IN CRORES) Change Change Change Revenue from Operations 30.32 14.36 23.29 -23% 62% 54.98 37.65 -32% Total Income 31.00 15.30 24.70 -20% 61% 56.33 40.00 -29% Operating Expenses 20.70 11.01 19.36 -6% 76% 38.07 30.37 -20% EBITDA (Excluding OI & EI) 9.62 3.35 3.94 -59% 17% 16.92 7.29 -57% EBITDA % 31.7% 23.3% 16.9% -1,483 bps -644 bps 30.8% 19.4% -1141bps Finance Cost 1.01 0.32 0.58 -43% 80% 1.95 0.89 -54% Depreciation & Ammortization 2.59 2.44 2.50 -3% 3% 5.01 4.94 -1% PBT 6.71 1.53 2.26 -66% 48% 11.31 3.79 -66% PAT 4.96 1.12 1.63 -67% 46% 8.41 2.75 -67% EPS (₹) 3.86 0.87 1.28 -67% 47% 6.55 2.15 -67% Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS Balance Sheet Summary PARTICULARS FY26 H1FY27 (₹ IN CRORES) Shareholders' Funds 163.02 165.79 Non-Current Liabilities 23.03 22.61 Long Term Borrowings 21.25 20.62 Current Liabilities 21.69 21.97 Short Term Borrowings 9.42 5.37 Trade Payables 9.44 14.84 Total Equity and Liabilities 207.74 210.37 Non-Current Assets 121.91 122.85 Tangible Assets 68.08 64.63 CWIP 12.38 16.30 Current Assets 85.83 87.52 Inventories 24.01 33.53 Trade Receivables 32.57 21.12 Cash & Bank Balances 13.45 17.36 Investments 12.45 11.38 Total Assets 207.74 210.37 Shree Ganesh Remedies Limited QUARTERLY HIGHLIGHTS Cash Flow Summary PARTICULARS H1FY26 H1FY27 (₹ IN CRORES) Cash from Operating Activities 17.66 14.64 Cash from Investing Activities -8.23 -5.17 Cash from Financing Activities -5.73 -5.55 Net Cash Flow 3.70 3.92 Cash at the Beginning of Year 11.12 13.36 Cash at the End of Year 14.82 17.28 Shree Ganesh Remedies Limited About the Business Excellence in Complex Chemistry 09 Unparalleled Expertise in Advanced Chemical Synthesis 10 Unmatched Technology Prowess In Complex Chemical Reactions 12 Tailored Solutions Through Mastered Chemistry and Technology 13 Strategic Product Selection Criteria 14 Our Evolving Business Model 15 Collaborating With Industry Leaders 16 Ankleshwar Site Expansion Fuelling Our Growth Strategy 17 Infrastructure at Ankleshwar Site 18 Dahej Land Acquisition Setting the Stage for Large Scale Projects 19 Driving Innovation Through Strategic R&D Investments 20 State-of-the-Art R&D Infrastructure 21 State-of-the-Art Pilot Infrastructure 22 Accreditations that Speak to Our Comprehensive Standards 23 Driving Innovation and Growth 24 Ensuring Health and Safety 25 Protecting the Environment With Sustainable Practices 26 ABOUT THE COMPANY Excellence in Complex Chemistry Established Expertise Strategic Expansions Over 21 years of excellence in chemical Continuous investments in new manufacturing manufacturing, specialising in pharmaceutical blocks and R&D centers to enhance production intermediates and speciality chemicals. capacity and innovation. Global Reach Trusted Partner Serving over 21 countries, including key Trusted partner for leading global companies, markets in the EU and the US, with a offering reliable and high [Showing first 8,000 characters — download PDF for full document]